166 related articles for article (PubMed ID: 35799399)
1. [Long-Term Survival of a Patient with Triple-Negative Breast Cancer with Hormone Receptor Status Conversion between Primary and Metastatic Tumors].
Hayashi K; Harao M; Ogihara K; Sasaki Y; Nishida S; Shiba S; Sakuragi M; Kitayama J; Sata N
Gan To Kagaku Ryoho; 2022 Jun; 49(6):697-699. PubMed ID: 35799399
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report.
Ishizuna K; Ninomiya J; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
BMC Res Notes; 2013 Jul; 6():254. PubMed ID: 23830415
[TBL] [Abstract][Full Text] [Related]
3. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
[TBL] [Abstract][Full Text] [Related]
4. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
5. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
6. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report.
Nahhat F; Doyya M; Zabad K; Ksiri H
BMC Womens Health; 2024 May; 24(1):285. PubMed ID: 38734591
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Triple Negative Breast Cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
[TBL] [Abstract][Full Text] [Related]
8. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
9. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
[TBL] [Abstract][Full Text] [Related]
10. [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Nakamura A; Shigekawa T; Asakawa H; Park K; Baba N
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1251-1254. PubMed ID: 34657057
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
12. Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.
Porter K; Rosenzweig MQ
J Adv Pract Oncol; 2017 Mar; 8(2):164-168. PubMed ID: 29900024
[No Abstract] [Full Text] [Related]
13. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer hormone receptor negativity, triple-negative type, mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy.
Sekine C; Nakano S; Mibu A; Otsuka M; Oinuma T; Takeyama H
Asian J Surg; 2020 Jan; 43(1):148-153. PubMed ID: 31153730
[TBL] [Abstract][Full Text] [Related]
15. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
17. [A case of malignant phyllodes tumor after surgery for breast cancer].
Hashimoto T; Okishiro M; Ishida T; Sato Y; Morimoto Y; Kusama H; Matsushita K; Kimura K; Katsura Y; Nitta K; Kagawa Y; Takeno A; Sakisaka H; Nakahira S; Taniguchi H; Egawa C; Takeda Y; Kato T; Tamura S; Takatsuka Y; Oku K; Goto T; Nagano T; Nakatsuka S
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1927-9. PubMed ID: 25731378
[TBL] [Abstract][Full Text] [Related]
18. [A case of locally advanced and metastatic breast cancer successfully treated with combination therapy of paclitaxel and bevacizumab].
Miki M; Matsuo Y; Yoshida S; Tane K; Hirokaga K; Maekawa Y; Takao S
Gan To Kagaku Ryoho; 2014 Aug; 41(8):1027-9. PubMed ID: 25132039
[TBL] [Abstract][Full Text] [Related]
19. [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
Nonomura A; Aomatsu N; Tei S; Haraoka G; Tsujio G; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Iwauchi T; Nishii T; Morimoto J; Nakazawa K; Uchima Y; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2056-2058. PubMed ID: 28133220
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
